FMTX - Earnings call transcript Q3 2021 | Forma Therapeutics Holdings Inc

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Good morning. Welcome to the Forma Therapeutics Third Quarter 2021 Financial Results and Business Update Conference Call. All participants are currently in a listen-only mode.

Following management’s prepared remarks, we will hold a Q&A session. [Operator Instructions] As a reminder, this call is being recorded today, November 12, 2021. to conference like Corso. to now would turn over the Mario I go sir. Please ahead

Mario Corso

Scientific operator. Corso, listeners Thank Investor is business third This you, Frank Chief Mario On our results financial Forma. Dave Officer; Chief today’s by to and President Officer; Todd Chief our Lee, Chief Shegog, morning and call, quarter Officer. to XXXX this joined Relations Executive Senior and Financial Good Medical Cook, our I’m to welcome Officer; our and Kelly, our Pat update. call review at of Director

Before or emphasize We Any are of the and planned during assumptions, forward-looking we potential our forward-looking financial enrollment, pursuant benefits of intended and made that call statements facts that begin, statements this I’d quarterly risks statements, to made Form Form statements, provided the events belief, due these uncertainties. like estimates, expectations and reports are uncertainties impact clinical Reform to during and reports historical and this or future and development subject or applicable and by could statements will to caution regarding Litigation provisions potential the information and Company XXXX business, plans, trials, statements except as clinical X-K. heading of the candidates, on ongoing including disclaims operations, of our reflect current nor under by with or current clinical business any for and and and statements Factors not regulatory our announcements business, filed certain data any forward-looking those ended and current to want product are Securities materially comments to the predictions are quarter listeners from update results to current conference XX, Actual guarantees on submissions, are various associated obligation relationships be Harbor financial of collaborators, including required forward-looking includes on Risk our today forward-looking in call, report success with XX-Q parties be our stated and subsequent that and conditions differ the COVID-XX September to Safe safety in Private our development, our of implied that with requirements, performance. our timing, Act law. those and neither the therapeutics, entitled capital third XXXX. such risks SEC The revise of our

like mention as Before turning the would to release. I activities outlined two in upcoming call today’s over Frank, to

I in We December next an also to briefing over at ASH will www.FormaTherapeutics.com. our the that our the Officer. call holding events on made Annual week. will Frank, on available XX, And be on With will virtually participating now trials Meeting. results the and website President to turn investor Further being be Conference presented information clinical Jefferies these will discuss be Executive London we Chief

Frank Lee

Good Mario. you, morning Thank everyone.

Forma with cancers. our the hematologic make rare progress continues purpose transform good disorders and to patients lives to on of

cell disease sickle other cancer acute leukemia. Our with and and myeloid for portfolio anemias, molecules transformative potentially hemolytic includes patients prostate

itself. to programs the progress cell have the pleased trusted Sickle October, collaborate resource the trials about clinical in for with patients about about be find to launch trial sickle clinical and trials and we clinical advancing a allows a in of process easily science, and Cell area with sickle Our as success. It term and finder. specific In establishing positions geographic sickle information enrolling Along for more I’m wealth complex of learn and catalysts the Forma clinical partner daunting with for clinical America Association trials, we’re long all to cell important cell the in community. sickle this our Disease the upcoming users making can growth cell progress a the

that sickle important to this part benefits the of entire We’re cell a community. be honored effort

Now I’d like to turn to the third quarter.

a along the of data First updated by action. completed activator our addressing our foundational anemia We’ve for to label not therapy be open with enrollment the mechanism once in blood with but health only completed disease MAD plan present X December. trial, sickle etavopivat in its potential cell disease to ASH at the the extension cell sickle daily Phase cell and the improving results PKR red multimodal by with

continue sites X/X VOC’s two our traditional endpoints, Hibiscus and and includes reminder, that pathway. study study as hemoglobin support in the open to Phase enroll co-primary approval this We and patients a

overall the study the development approval patients discussions timely patients, non development meaningful cell ensure of to thalassemia, And pediatrics addition, plan package. plan based submission clinically on information to and potential endpoint etavopivat both with In program, closely the designed a in accelerated which dependent, by FDA approval. discussions months, Based that progress XX the the additional given is of down time sickle above, to and on dependent and provide accelerated includes we potential planning of a emerging differentiated be dependent. design FDA, includes We’ve recent as patients action for pipeline our a cell pursue also have transfusion data to has sickle made age of transfusion the provide which believe for the and are a to and to a program, hemoglobin approval a Hibiscus moving data, support six with we comprehensive to which product surrogate transfusion age study sickle unique provides etavopivat. productive had forward in mechanism and collaborate the on cell and

In additional addition, studies underway. for planning is

with inhuman we ongoing the inhibitor metastatic an important milestone in presentation the Turning triple our October trial prostate FT-XXXX, in to reached X our phase castration from CPB/pXXX cancer. first resistant meeting of results

from response. present development the the early we support compound, ASH. novel relapsed the third by These a AML to cohort our of the FT-XXXX for pathway duration potential differentiated for We at of target respect given further data inhibitor particularly for the combination data are data With inhibition. Olutasidenib azacitidine IDH profile, encouraged impressive and to potential to offer to Olutasidenib CPB/pXXX the plan refractory new the

to We submission. for a also continue application in new drug good make preparation progress

Looking months. forward Olutasidenib. ASH share In December to I’m events present the and key over plan at presentations pleased etavopivat coming to we some four on

addition Thalassemia plan In which and sickle to study, cell transfusion we transfusion dependent end, patients patients the year by dependent phase X independent. start and includes both

FT-XXXX of half prostate plan year XXXX host to And one. in first study X cancer. study courage etavopivat plan to we sickle start day. analysis cell to our in the data additional we later plan study to we into Mid Going first have R&D and pediatric the next XX Hibiscus our have Phase from interim

as many in of part pandemic created impacted now the of the to substantial We’re reside latter for we by has discussed sickle challenges for whom both cell guiding and COVID-XX sites the before areas trial patients, the XXXX pandemic. clinical disproportionately

disorders lives our We’re call employees healthcare cell workers, ongoing living improving conditions With patients, observing rare the acknowledge the the very like community. that, over challenges purpose with over sites time, helped to and Pat. including hematologic cancers. patients transform the we pursue as working are of sickle I’ll closely our And posed investigators, to pandemic those I’d clinical and to the the with navigate turn by have and COVID-XX and who

Pat Kelly

These disease. ATP, that the multimodal of X, that events health development goal for distinct outline sickle characterize disease. I sickle to selective to potential the and deoxygenated would significantly provide and disease. anemia cell then analysis reducing effects mechanism both We believe in binding we the the from program has and inflammation the to our that reduce allows meeting characterize on lifespan. the Frank. of debilitating etavopivat activator multiple hemoglobin-S. cell will data occlusive the in good reduce with brief caused and mechanism it The programs sickle dosing increase a in RBCs action. the generate This events and reduced will of that may etavopivat increased the X-DPG course the morning X-DPG cell and thus for with And PKR improvement overview believe been the ATP lifespan everyone. cell membrane clinical etavopivat direct you, incurred and effects in a may of the ultimately cell to support the presentation to hemoglobin-S decreases a and daily RBC Olutasidenib of sickle the RBC of has by sickling. December. risk cell improve and vaso vaso improving by sickle daily etavopivat The which then important disease anemia decreases cells decreased associated improving Etavopivat Thank hemolysis polymerization, scheduled cycles oxygen multimodal is sickling repair ASH damage X, our formed modifying through of an chronic through an rigid RBC sickle once disease is hypercoagulability occlusive structures health the by of and Together the thereby

also numerous red have by health. markers as of cell elucidate of etavopivat sought sickle We RBC measured the on the to effects blood

the week rigorous who We two for dosing June phase recently oral X at abstracts clinical program meeting and month. presentations patients presented following week have in updated in and we the with pleased have in were observed EHA in etavopivat the who ASH data comprehensive designed key have a and the the Atlanta cohort. the accepted been at and cohorts next etavopivat clinical have data completed data meeting patients XX in The completed dosing our

disease. of hemoglobin that a at XX% patients this than weeks demonstrated sickle per five cell out of XX six etavopivat of treatment daily or levels completing In gram patients etavopivat has hemoglobin been previously maintaining one deciliter hemoglobin increase dosing of weeks open label sustained with have with in improvement. cohort, greater two XX% response We can

and two are etavopivat RBCs counts the of dosing lower of improved sickle levels has early improves response. RBC of this significant healthier sustained and of the significantly improved delay of dosing. the hemoglobin in living affinity weeks to markers along compared improvements to patients daily into receiving as RBC We are in reduction reduction pretreatment absolute weeks shown sickling improves and RBC in a etavopivat hemolysis that sickle This to patients and XX reduction the a an etavopivat etavopivat and two with the with longer, the deformability reticulocyte in translated are the oxygen receiving significant seen deformability leading of weeks sickling RBCs indicating as levels. These also the in point dosing a have oxygen

disease. reported In in treatment addition hemolysis, reduction weeks hemoglobin our markers systemic in cell by coagulation our vaso This etavopivat health daily. improving to etavopivat have that etavopivat daily characterize receiving dosing chronic XX and with is inflammation RBC patients we and occlusive observations the that sickle to the supports encouraging events hypothesis, up of initial that of improved the data sickle debilitating reduce of produce we the that can of may

previously daily XXX% as Finally, is dose which higher doses etavopivat underlying up of milligrams disease. consistent in profile evaluated maximum reported, tolerated cell being that the is to the is that sickle the with dose safety a with study daily XXX well

presentation, etavopivat hospitalizations dosing profile safety for As on a of while rate no been EHA events has noted in etavopivat treatment. any the at vaso the observed notable adverse XX cohort occlusive the with week for of VOC patients our in of grade low

relative bilirubin markers dose the will milligrams Looking prior an of related hemolysis of to will XX evaluating XX patient’s hemoglobin VOC be weeks, updated meeting. requiring effects weeks, exposure With sickle of XXX patients XX the reticulocytes, This hospitalization. to cell patients’ from of and adverse up open three etavopivat history results etavopivat LDH, the approximately XX markers label month, results on for years including to include in we on ASH provide presented up extension forward treated analysis next the annual the and profile at inflammation patient systemic their event will coagulation. for

analysis evaluated analysis ID relapsed the mutant being in myeloid patients Earlier with positive our an characteristics of refractory Olutasidenib, patients. twice refractory registration Olutasidenib ASH receiving acute in results the the presented phase these milligrams AML. to relapsed turning were to of the At Atlanta, upcoming leukemia AML we in Now will XXX inhibitor meeting of daily. or this Olutasidenib inner from provide molecular to response in year, of HX patients

population, I’m will receiving cohorts be addition with now update turn from to combination treatment various call will AML azacitidine prostate sub for the cancer. an showing including of who in in that, benefits also on With to patients. In at naive meeting combination the over Dave, the going ASH results presented, FT-XXXX Olutasidenib provide

Dave Cook

a potential a of discussing to pathway I’m care address of expressing AR potential has by via the few seen the splice inhibitors. resistance of applicable for FT-XXXX Pat. broad are hormone domain. to novel AR means modulates Thanks, believe lacks CPB/pXXX going receptor domain, no antigen for We inhibitor action This the CPB/pXXX stage spend the signaling tumors which is next or which the to there targets the mechanisms, resistance the our mechanism FT-XXXX that for minutes standard many mechanism range because example, the binding C-terminal targets mechanisms AR-vX AR XXXX. FT-XXXX. clinical of therapeutic for N-terminal variant the approved treatments, of and

of addition, of In cancer milligram to seven enroll doses October designed first with encouraging of these therapy FT-XXXX CPB/pXXX trial. drug XXXX. as X as year. for We a profile to week on lines higher the began in earlier up dose, study of efficacious of quarter and triple have use potential These the tolerability many modeling standard dose upon predefined titration pathway. safety initial cancer. measures of in an off care. on the cycle the XXX safety both support many its to based in and XX starting profile of of phase meeting Abiraterone of instances may three concentrations a typically prostate is design combination week prostate enrolling presented the were based encouraging as failed eight to of and and The are pharmacodynamic achieved X tolerability in as inhibition with a entering And this well with that at men Enzalutamide or at therapy also consistent prior one one study. predicted utilizes receiving metastatic for Data enrolled September least as our The one in with and milligrams, an preclinical trial line with criteria. presented resistant chemotherapy adaptive in The looked approached open castrate data. pretreated heavily men the dose biologic effects results men showed The XX in the on

In biopsies All pathway. a in addition, treatment with of emergent events CPB/pXXX managed. key in three but to of were innovation one or patient two reduction demonstrated no discontinuation. experience grade was emerged marker lower the grade events skin medically acetylation leading histone a treatment One of hyperglycemia the which adverse a treatment

of patients more Todd. to nodal decline at XX a reduction, enrollment as confirmed a this share by remained this radiography. Notably, response this to next greater and represents than dose XX the than the prior Following progressing experienced to weeks plan the PSA patient of trial. on was was results greater at our turn Financial I’ll now and which treatment over XX% and stable scientific toward XX% call classified valuable in of Chief Officer, His tumor, a year. weeks. comprehensive first conference We disease middle

Todd Shegog

then Thank position few and XXXX outlook. to and you, today’s you a joining of for our discuss for on the Dave. And third spend thank first us I minutes everyone our financial results will discussing quarter call. cash

XXXX. million, net ending spending programs, for quarter in XX, increased XXXX employee the The preclinical well loss of clinical XXXX. development expenses September support primarily and compared attributable by R&D hiring compared staffing September expenses million and ended costs September XXXX, $XX.X to as XX, costs General $XX.X for support were equity development quarter million $X.X and our September September the the $XX.X our equity and professional XX, quarter based for attributable XXXX, operations. quarter for September the compensation net development was programs. to was was compensation, XXXX. to compared was $XX.X of Research which ended increase net for $XX.X staffing, to The million based preclinical primarily to and clinical the as for million fees. quarter loss ended XX, ended were loss million a Our driven quarter This XX, ended XX, and for administrative increase the to increased

Overall, continue XXXX, XX, quarter requirements end Cash can as balance a we use in million marketable reflects and cash, XXXX. to of equivalents position now the of and in compared support through Operator, year third with quarter to questions. million, funding capital Our at strong securities operations. expenses $XXX.X we take operating cash financial to September be working $XXX.X the XXXX. was

Operator

coming Mark Thank line question the Instructions] first with you. of Now Oppenheimer. from [Operator Breidenbach

is line Your open.

Mark Breidenbach

morning, much good taking Hey, questions. the so for and thanks

from allowing is color appreciated. more would couple on based be? accelerated I with give would a Can that information that type PSA information decision to observation I the you the triple of patient, the cancer Thanks XXXX. have me, program that prostate was start A this question on PSA comment Just we decline some definitely the guess on thoughts level to saw of the response. hoping I ask hemoglobin meeting. what presented discontinuing was be actually see that Dave would regard that additional the would little much. making data appreciated. the the on around FDA to observation on And could bit starting enzalutamide early an before and indication second responding so Maybe the to us approval be before the want maybe spontaneously after at

Frank Lee

the It’s question, for Lee here. Mark. Thanks Frank

then of me it Pat hand to color. over Let question the first provide the first additional part to address and

patients. before quickly as strategy many talked most to label as patients the is pursue as about possible First, there and differentiated possible get our as to we possible help for as

to And so few said, want I make a with that things clear.

changes co-primary the current mentioned, design VOC and the plan time. path. that the And two or reminder, study Hibiscus a for have support includes traditional this as hemoglobin at we current endpoints, I no study First, quick approval

accelerated generate endpoint. provides a that hemoglobin to it the also be the data as surrogate on able which before, as to on In we’ve pursue about potential an going dependent we’re addition is now, approval talked to

will similar And my mentioned And it’s as remarks, based unique I additional get on on discussions accelerated of with drug opening of as are and believe information with a there hemoglobin action. And pass patients plan path. development speed in think very mechanism approach possible. be providing and pursuing that mechanism to we on I recent the said, etavopivat’s to endpoint again accelerated surrogate for FDA, action, and that other for specific we the is benefit, approval some we believe also the which both And clinical as try molecules worthwhile for a required so traditional viable. quickly as unique

it color let that that type provide turn the to we over to me So said, Pat, of provide. some data additional could on potentially

Pat. So

Pat Kelly

Yes. a of these CNS, and are studies Frank. think in renal Frank cell just I complications Yes of life looking potential always broad what as disease sickle others. has progress. considered endpoints number to related profile explore etavopivat echo efforts Thanks differentiating disease of at part opportunities said, and and many that meaningful cycle our of just clinically cardiopulmonary, And include the these could already we’ve

We’re sickle etavopivat initiating transfusion well trials. the with as dependent our as cell pediatric study

mechanism that support our sickle well package response a or disease. complete of action. as able in feel the data to Hibiscus lot epidemiological a its broad of that these the help information very from that studies, potential have the efforts as from trial, imagine unique additional So we there’s cell benefits be also we’ll can you experience But through etavopivat of hemoglobin and

the of broad includes, turn that information be it’ll set it to as information very from as community. our believe, package studies, we a so I’ll over in a Dave. well own derived And

Dave Cook

or good transient looked Thanks our question in in of can it’s known we on whether on Hi. a response line there’s why deprivation at a that And for XXXX. And very X% a withdrawal which based to number that to upon androgen about happens reasons spontaneous phenomenon the case everyone this on Yes multiple else for carefully patients. with investigators was And clarify just have morning patients your Mark. here. androgen were small the not of was establish there excluded.

with androgen has an you FT-XXXX. to And really prior time being inhibitors the androgen that signaling is and half would before have treated The on three from deprivation coming do was with to a to Enzalutamide, last seen patient of duration, duration withdrawn study. kind first the about response months

very there rate in The PSA clear, of second, it’s a the decline. was market change

And stabilized. level most interval a was by important establishment a of of it XXXX. radiographically of and fact, sharp evaluated patient’s stopping sort was PSAs XXXX, starting thing was treatment was followed upon In perhaps increasing FT-XXXX, third that the to size, shown between treatment decline in is and the very during only it with growth rate that tumor nodal be Enzalutamide upon and of

lines other lot clearly is think of So based a with course evidence response phenomenon. of multiple we discussion, some and and that a those of on to that XXXX in not this

Operator

coming And from Maury with line the Jefferies. our of Raycroft question next

is line Your now open.

Maury Raycroft

morning, a that for following for questions. Hi, on novel up my thanks to a be etavo for would this etavo the potential based question prior everyone. and on a just precedent information Good showing is additional for specifically? and you this taking I’m there FDA endpoint is clarifying or

Frank Lee

Well could broadly clinical mentioned, on this is those the as also FDA a our this of discussions clinical to Pat articulated or epidemiologic we number information. collect and mechanistic etavopivat certainly as kinds and data based Pat have include trials of on and certainly with recent

and you So know kind background here. of don’t have additional I thoughts Pat, that if that’s context

Pat Kelly

end there’s always field an a and remarkable, be mechanism, forward we opportunity base as ongoing important new the points mechanism FDA any with guess of will to with with going patients I the I discussion and think should is with is that’s part believe what very opportunities the we be push cell to that I careful Yes, evolved new this this discussions feel broad that some benefit FDA. or part sickle the of

Maury Raycroft

maybe to data than include collect to there’s though support an is accelerated planned earlier path? the even that to VOC approval and design, possible plan then, And informally no just it

Frank Lee

Pat Go I don’t yes. ahead think.

Pat Kelly

to don’t a that say have in position I think was of to detail. I level we’re going just

support said, these discussion FDA. intended Frank the efforts. think, as part with of design our is And be I of to the study current the that’ll Hibiscus

Frank Lee

starting two we’re study next FAO of early populations. dependent data next as start mentioned, pediatric well as the the different certainly, year, patient early study to transfusion sickle be as and the also year, totality we’ll this we going cells into the year, And the the

So the overall. of be in the will totality will important data be discussions

things, we’ve as In we’ll observed analysis treatment presentation, ASH Pat among as have VOC patient’s mentioned, history addition, well. on baseline at an of what the versus other

Operator

next coming question Alethia of line the from Cantor Our with Young Fitzgerald.

Your is line open.

Alethia Young

case. guys, thanks do have question, just One, Hey, to seen perspective you. similar possibility your wanted for a why Thank get of the a get the then, taking XXXX, talk or and to that about the like the the based maybe path little couple. on we there haven’t be about profile? kind my the went dosing wanted with the on taper pathway Pacific a bit on forward, might And just VOCs you bit I really faster I as for mutational people So little in is some class? other off

Frank Lee

So the Pat, maybe you first question? want take to

Pat Kelly

period, a an disease it’s study. highlighted Yes, well them tolerated have any trot we treatment June extended be low in our on which under related In washout there is vaso taught Patients by that pain did sickle of molecule. the had events investigator we presentation to as related in we for I the very occlusive weeks, four follow rates under cell think the to we’re very events.

it. modifying disease you away you many The of connotations when think to recurrence a has will see take role a of disease. that different I taper therapy,

that has and reduced, they they’re and that patient patients should of longer the that investigator now energy, be to protected. themselves better doesn’t in may caution function the setting no discontinuation position to a been taking with more has our feel make be the what makes sure part away over because of the that patient because the medication that part think I of their exert capacity

seeing that And well. ASH the that’s been further at update a lovely meeting so and provide as we’ll on

Frank Lee

Dave?

Dave Cook

obviously, always to Sure. Hi for development. accelerate we’re looking ways XXXX Alethia, regarding

see the because yet combination tolerability the is last and particularly its point largest the but of safety I that things analysis, and phase a days hyperglycemia splicing pointed opportunity three and isn’t integrated out, lead pay susceptible patient one study. then may to sub in in in think and as course move our so standard terminal And thing of to but still to at and with genetic a a grade point AXc triple full And the over care. think in responder fully groups. of the every patient upstream meeting, note attention XX was that profile, patient for the to identified, far well thus And had about mutation being one the one the I’ll high. analysis and we is who AXc the of had the it that identification that as AXc an previous Enzalutamide terminal other was AR particularly was of I’ll out got said, or did with XXX in associated C note the the I and it’s measure was That hemoglobin domain analysis to a the is days. early, this course, maybe drug very thing mutation resistance. is we’ve C

insulin Type X this was So on diabetes, or a truly potentially it’s pretty clear undiagnosed to had treatment. emergent who and patient not either was resistance us that

hadn’t it AE. previously, since hadn’t, been it as a seen However, treatment-emergent classified is

happy with profile. an really we’re the to lead So that set safety And expanded may for opportunity XXXX.

Operator

[Operator the Robin line Craig-Hallum. question Garner Our next of coming with Instructions] from

Your line open. is

Robin Garner

studies to this any? might please? Are to of studies hope from Thank show female, design else what transfusion to about sickle the those you. is any changes ask cell in and upcoming patients you there there dependent the I wanted in

Frank Lee

provide perhaps you Pat, can there. quick So overview a

Pat Kelly

on of cell sickle patient’s transfusion the patient Sure. transfusion transfusions. cohorts a patient for disease phase prevention. that either sickle understand hemoglobin effect blood three are transit with stroke It’s the changes including or the no the a primary to the a population chronic the for on setting need reducing of design. the and It’s maintaining cell on patients dependent who been and dependent population as etavopivat secondary pilot biology two and and transfusions specifically a Thalassemia frequency have to for in well level non There just quickly, very or as chronic

study So that transfusions the affect while blood to we hemoglobin-S infusion, controlling it’s iron, patient for question, a can a levels. population need ask their

Frank Lee

approximately And add, dependent. I’ll transfusion of patients just are sickle XX% cell

significant need. it’s a So

Robin Garner

for to for the durability was might understand And any that the example, on the have update study, who patient, that been data the the already do presented, of response responder that helping us XXXX in to passed patient that’s today? you

Pat Kelly

We salami friend don’t as update. expect want said updates. to guided of slicing. don’t be have fact, And Yes. we ours We in regular any to not

data individual We’re going with sets patient to to try opposed as to vignettes. come robust back provide

will So of in where we that’s be future. where kind the

Frank Lee

discussed And, substantial more to mid next XXXX. update broadly provide a as to we on before, getting we’re year,

we So forward that. look to

Robin Garner

And what could to steps is that need you submit occur for addition NDA question my Olutasidenib? last in just before

Frank Lee

We package, very-very progress. working the good NDA made on been and we have

that. I’ll So say

So the we Olutasidenib carrying I make obviously, always we be sight will sure NDA that a collaboratively line pursuing marketing certainly the NDA with that because be product. partner we strategy can said forward and have that to of and we’ve partnering the the eventually important, very are think and partner the to would file

part strategy And made overall of progress good very is so we’ve Olutasidenib strategy. our still and

So stay tuned.

Operator

Lee back time. Frank this closing at the turn further over will remarks. now I’m Mr. for showing call any like no to I questions to

Frank Lee

in have great today’s more hematologic progress to and forward call on today’s all. thank our three everyone for concludes and the on to this programs focused time XXXX cancers, you taking third and development participate a We certainly made day. good during diseases we of Well, sharing rare the Thank compounds on look and quarter progress call.

Operator

gentlemen conference does and for Thank Ladies you your for participation. today. that conclude

may You now disconnect.

Forma Therapeutics (FMTX) 12 Nov 212021 Q3 Earnings call transcript